Xtant Medical Holdings, a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and wound care disorders, has announced the commercial launch of CollagenX, a bovine collagen particulate product designed for surgical wound closure.

CollagenX is engineered to promote healing, prevent dehiscence and help mitigate concerns related to surgical site infections.The product can be used across a broad range of surgical procedures, complementing Xtant’s existing biologics portfolio while also extending its application into other surgical disciplines.

Sean Browne, President and CEO of Xtant Medical, stated, "The commercial launch of CollagenX for surgical wound closure enhances our extensive orthobiologics portfolio and demonstrates our dedication to innovation in meeting the diverse needs of surgeons and patients.”

“As one of the few fully vertically integrated regenerative medicine firms, we are uniquely equipped to deliver the quality and consistency that can significantly improve patient outcomes,” he added.

The company plans to release its financial results for the third quarter ended September 30, 2025, before the start of trading on November 11, 2025.